REMARKS

The present amendment is submitted to reduce the issues on appeal. Claims 1-3 and 13-17 are cancelled, claims 4 and 5 are rewritten in independent form, and claims 18-21 are amended to correct their dependency. A Version With Markings Showing Changes Made is attached. As these changes do not involve any introduction of new matter and do not raise any new issues on appeal, but rather reduce the issues on appeal by reducing the number of claims, entry is believed to be in order and is respectfully requested.

Respectfully submitted,

Holly D. Kozlowski
Registration No. 30,468
Dinsmore & Shohl LLP
1900 Chemed Center
255 East Fifth Street
Cincinnati, Ohio 45202
(513) 977-8568

Version With Markings Showing Changes Made

Claims 4, 5 and 18-21 are amended as follows:

4. (Twice Amended) [The composition according to claim 1,] A composition for the treatment of glaucoma and ocular hypertension comprising a therapeutically active and physiologically acceptable amount of a prostaglandin analogue which is a selective agonist for EP_1 prostanoid receptors, or a pharmaceutically acceptable salt or ester thereof, wherein the prostaglandin analogue is 15(R,S)-16,16-trimethylene-PGE_2 or an alkyl ester thereof.

5. (Twice Amended) [The composition according to claim 1,] A composition for the treatment of glaucoma and ocular hypertension comprising a therapeutically active and physiologically acceptable amount of a prostaglandin analogue which is a selective agonist for EP_1 prostanoid receptors, or a pharmaceutically acceptable salt or ester thereof, wherein the prostaglandin analogue is 13,14-dihydro-17-(3-fluorophenyl)-18,19,20-trinor-PGE_2 or an alkyl ester thereof.

18. (Amended) The method according to claim [6] 8, wherein R is C_{1-10} alkyl, C_{3-8} cycloalkyl or aryl-C_{2-5} alkyl.

19. (Amended) The method according to claim [6] 8, wherein R1 is C_{3-7} cycloalkyl or C_{3-7} cycloalkenyl.

20. (Amended) The method according to claim [6] 8, wherein R2 is hydrogen, hydroxy, methyl, ethyl, methoxy or OCOR4, wherein R4 is C_{1-10} alkyl or C_{3-8} cycloalkyl.

21. (Amended) The method according to claim [6] 8, wherein R3 is a straight or branched chain saturated or unsaturated alkyl group having 3-8 carbon atoms, optionally interrupted by one or more heteroatoms selected from the group consisting of oxygen, sulfur and nitrogen, each carbon atom optionally substituted with a substituent selected from C_{1-5} alky, hydroxy and carbonyl groups, wherein the hydroxy and carbonyl are attached to carbon 15 of the prostaglandin structure, and said alkyl group optionally containing a C_{3-8} cycloalkyl, optionally mono- or independently tri-substituted with C_{1-3} alkyl, C_{1-3} alkoxy, hydroxy, nitro, trifluoromethyl or halogen.

749159